Publications by authors named "D Voliotis"

Claim this Profile
E
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix, Jean-Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Dimitris Voliotis

J Hepatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Ann-Lii Cheng, Zhongzhen Guan, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Dimitris Voliotis

Eur J Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Jean-Luc Raoul, Jordi Bruix, Tim F Greten, Morris Sherman, Vincenzo Mazzaferro, Dimitris Voliotis

J Hepatol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
Ghassan K Abou-Alfa, Dino Amadori, Armando Santoro, Arie Figer, Jacques De Greve, Dimitris Voliotis

Gastrointest Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Dimitris Voliotis

Lancet Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis